Literature DB >> 2285498

Survival after unexpected high serum methotrexate concentrations in a patient with osteogenic sarcoma.

D J Grimes1, M R Bowles, J A Buttsworth, D B Thomson, P J Ravenscroft, P F Nixon, R F Whiting, S M Pond.   

Abstract

An 18-year-old female patient receiving adjuvant chemotherapy for osteogenic sarcoma developed a pruritic erythematous rash during infusion of the eighth dose of methotrexate (8 g/m2) in the series. In other respects, the infusion proceeded normally but the 24-hour serum concentration of methotrexate was unexpectedly and extremely high, 574 mumols/L. Dosing error was excluded, as was the hypothesis that the high concentrations were due to the presence of methotrexate-specific antibodies. Acute oliguria and renal failure were the primary manifestations of the drug-induced toxicity and the high concentrations can be attributed to decreased renal elimination of the drug over the first 24 hours. Treatment consisted of folinic acid rescue, forced diuresis, sequential charcoal haemoperfusion and haemodialysis, and repeated oral doses of activated charcoal. After examination of the contribution of the extracorporeal procedures and the charcoal to the elimination of the drug, the relative lack of morbidity was attributed primarily to the folinic acid rescue and the intensive supportive care.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2285498     DOI: 10.2165/00002018-199005060-00005

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  22 in total

1.  Isolation of pure IgG1, IgG2a and IgG2b immunoglobulins from mouse serum using protein A-sepharose.

Authors:  P L Ey; S J Prowse; C R Jenkin
Journal:  Immunochemistry       Date:  1978-07

2.  Role of repeated oral doses of activated charcoal in clinical toxicology.

Authors:  S M Pond
Journal:  Med Toxicol       Date:  1986 Jan-Feb

Review 3.  Clinical pharmacokinetics of methotrexate.

Authors:  D D Shen; D L Azarnoff
Journal:  Clin Pharmacokinet       Date:  1978 Jan-Feb       Impact factor: 6.447

4.  Renal toxicity of methotrexate.

Authors:  P T Condit; R E Chanes; W Joel
Journal:  Cancer       Date:  1969-01       Impact factor: 6.860

5.  Incidence of drug-related deaths secondary to high-dose methotrexate and citrovorum factor administration.

Authors:  D D Von Hoff; J S Penta; L J Helman; M Slavik
Journal:  Cancer Treat Rep       Date:  1977-07

6.  Protein-methotrexate-IgG complexes in the serum of patients receiving high-dose antifolate therapy.

Authors:  M da Costa; W Isacoff; S P Rothenberg; M P Iqbal
Journal:  Cancer       Date:  1980-08-01       Impact factor: 6.860

7.  Folinic acid: pharmacokinetics and pharmacodynamics.

Authors:  P F Nixon
Journal:  Clin Exp Pharmacol Physiol Suppl       Date:  1979

8.  Renal clearance of methotrexate in man during high-dose oral and intravenous infusion therapy.

Authors:  N Christophidis; W J Louis; I Lucas; W Moon; F J Vajda
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333

9.  Methotrexate-induced renal impairment: clinical studies and rescue from systemic toxicity with high-dose leucovorin and thymidine.

Authors:  H T Abelson; M T Fosburg; G P Beardsley; A M Goorin; C Gorka; M Link; D Link
Journal:  J Clin Oncol       Date:  1983-03       Impact factor: 44.544

10.  Modification of human serum albumin binding of methotrexate by folinic acid and certain drugs used in cancer chemotherapy.

Authors:  P Coassolo; M Valentin; M Bourdeaux; C Briand
Journal:  Eur J Clin Pharmacol       Date:  1980-02       Impact factor: 2.953

View more
  2 in total

1.  The utility of online haemodiafiltration in methotrexate poisoning.

Authors:  Mohamed Said Abdelsalam; Mohammed Mahdi Althaf; Osman Alfurayh; Irfan Maghfoor
Journal:  BMJ Case Rep       Date:  2014-05-23

2.  Extracorporeal Treatment for Methotrexate Poisoning: Systematic Review and Recommendations from the EXTRIP Workgroup.

Authors:  Marc Ghannoum; Darren M Roberts; David S Goldfarb; Jesper Heldrup; Kurt Anseeuw; Tais F Galvao; Thomas D Nolin; Robert S Hoffman; Valery Lavergne; Paul Meyers; Sophie Gosselin; Tudor Botnaru; Karine Mardini; David M Wood
Journal:  Clin J Am Soc Nephrol       Date:  2022-03-02       Impact factor: 10.614

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.